News

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

Nearly 75% of patients suffered eye infections following the event.

The study underscores the potential benefits of early detection of pathological changes in the retina and choroid before ocular symptoms manifest, particularly highlighting the promise of choroidal vascularity index as a robust evaluation tool.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

First-in-human feasibility study.

AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.

The Women in Ophthalmology (WIO) survey by Johnson & Johnson Vision uncovers barriers faced by female ophthalmologists.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.

Sterile corneal ulceration is a rare complication of rheumatoid arthritis and may lead to corneal perforation. However, surgeries performed to restore vision often are not successful.

The general public should use caution when reading AI-generated medical information as it may be inaccurate, misleading, or biased.

Peter K. Kaiser, MD, shares a promising outlook for patients with dry age-related macular degeneration, with innovative therapies in development that have the potential not only to prevent vision loss but also improve visual acuity.

A new study focuses on the specific visual field conditions and defects that can result in an increased risk of vehicular accidents, particularly in the aging population.

Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.

Cataract surgery can alleviate the risk of dementia in visually impaired patients, especially those who are younger and male.

Ophthalmology experiences lower burnout rates compared with other medical fields, but the profession is not immune to the issue, explains Peter J. McDonnell, MD.

Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

Ab-interno implantation of a supraciliary allograft bio-tissue successfully reduced intraocular pressure (IOP) with comparable safety to other minimally invasive glaucoma surgical (MIGS) procedures

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco. Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden.

The company presented topline Phase I/II first-in-human results at the 127th American Academy of Ophthalmology annual meeting in San Francisco, demonstrating significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision.

At the 127th American Academy of Ophthalmology annual meeting in San Francisco, Alcon revealed the full U.S. commercial availability of its cloud-based cataract planner, building on its leading image-guided clinic to OR connectivity.

According to the study, detailed in presentations at the American Academy of Ophthalmology’s annual meeting in San Francisco, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.